Amyl Therapeutics

Amyl Therapeutics develops a fusion protein platform designed to treat amyloid related neurodegenerative diseases including Alzheimer's and Parkinson's. The Li�ge based biotech closed an �8.25 million Series A extension in September 2026, bringing its total funding to �27.85 million.